In a significant move for the future of healthcare innovation, AilsynBio has announced a strategic partnership with Dong-E-E-Jiao Co Ltd to accelerate the development of next-generation medicines using artificial intelligence.
The agreement was officially signed at Hong Kong Science Park, marking a major step toward integrating advanced AI capabilities with Traditional Chinese Medicine (TCM).
Bridging AI and Traditional Chinese Medicine
The collaboration aims to combine AilsynBio’s AI-powered drug discovery platform with Dong-E-E-Jiao’s expertise in traditional medicine to create more effective, evidence-based treatments.
This partnership reflects a growing trend in the global healthcare sector — leveraging artificial intelligence to modernize traditional healing systems and improve drug development outcomes.
Industry Leaders Back the Collaboration
The signing ceremony was attended by key stakeholders from across academia, industry, and research, including representatives from:
- China Resources Pharmaceutical Group
- Hong Kong Science and Technology Parks Corporation
- The University of Hong Kong
Their presence highlights the importance of cross-border collaboration between Mainland China and Hong Kong in advancing healthcare innovation.
Leadership Insights on the Partnership
Dr. Bo Chen, Chief Scientific Officer at China Resources Pharmaceutical, emphasized the strategic importance of the collaboration:
“This initiative represents a deep integration of industry, academia, and research in ‘AI + TCM’. It will help transform traditional medicine from empirical practices into evidence-based solutions.”
Meanwhile, Liang Zheng, Vice President of Dong-E-E-Jiao, highlighted the brand and product impact:
“This partnership will strengthen the scientific foundation of our products, especially in women’s health, and accelerate our transition toward technology-driven innovation.”
Pierre Wang, Managing Director at HKU’s Versitech, added:
“This collaboration showcases how Hong Kong’s academic research can translate into impactful global biotech solutions.”
Read more here: From ₹4 Lakh to ₹42.5 Crore: How a Family Trio from Surat Built India’s Gymwear Revolution
Ruchi Kumar is the associate editor at Entrepreneur News Network and TVW News India, where she leads editorial strategy, brand storytelling, and startup ecosystem coverage. With a strong focus on innovation, business, and marketing insights, he curates impactful narratives that spotlight India’s evolving entrepreneurial landscape. She has written extensively on fintech, AI and emerging startups.
